PCSK9 and non-small cell lung carcinoma: Our work demonstrated that aside from being related to poor response, high PCSK9 expression in baseline NSCLC tissues was also an independent risk factor for both PFS and OS in advanced NSCLC patients with anti-PD-1 immunotherapy.